ARTICLE | Company News
Panax Pharmaceutical Ltd., Sangen Pharmaceutical Co. deal
April 15, 2013 7:00 AM UTC
PANX and privately held Sangen will merge contingent upon the raising of $10-$15 million in a private direct offering.
PANX's lead product is a tablet for clearing the colon prior to colonoscopy. PANX said the product is poised for Phase II/III trials and anticipates filing an NDA within 18-24 months. ...